The Pemetrexed project is a clinical registry of patients with mesothelioma who have been treated with pemetrexed. The Czech Society for Oncology (CSO) and the Czech Pneumological and Phthiseological Society (CPPS) are expert guarantors of this project. Objectives of the project involve monitoring treatment safety and effectiveness, making it possible to analyze epidemiological characteristics of cancer patients and their treatment response, to model the influence of risk factors on survival, and to perform a detailed analysis of adverse reactions. Moreover, the project has become one of the projects that assess and monitor health care results and quality within the Czech National Cancer Control Programme; therefore, this project will also aim to improve the quality of life of patients with lung carcinoma and mesothelioma.

Expert council of the project

  • prof. MUDr. Miloš Pešek, CSc.
  • doc. MUDr. Petr Zatloukal, CSc.
  • prof. MUDr. Luboš Petruželka, CSc.
  • doc. MUDr. František Salajka, CSc.
  • prof. MUDr. Jana Skřičková, CSc.,
  • prof. MUDr. Vítězslav Kolek, CSc.
  • MUDr. Jaromír Roubec, Ph.D.

Project objectives

  1. Monitoring the overall number of patients treated with pemetrexed in the Czech Republic.
  2. Safety assessment of treatment with pemetrexed.
  3. Effectiveness asssessment of treatment with pemetrexed.
  4. Analysis of patient survival in relation to monitored clinical factors.
  5. Analysis of patient cohort treated with pemetrexed in relation to reference population-based data of the Czech Republic.

Institute of Biostatistics and Analyses Ltd, a spin-off company of the Masaryk University, provides management and other services to this project.